CVS Stock Analysis — CVS Health
Sector: Healthcare
AI Verdict
CVS trades at 12.9x next year's earnings while analysts expect earnings to triple, so you're getting a cheap price for massive growth if the integrated healthcare model delivers as promised.
Competitive Moat
CVS Health combines a national pharmacy chain, insurance arm (Aetna), and pharmacy benefits manager, creating a vertically integrated healthcare platform that locks in customers across multiple touchpoints. This integration makes it difficult for competitors to match CVS's scale in both retail access and healthcare data.
Summary
A 252.2% jump in expected earnings is driving a sharp reset in valuation expectations for CVS.
Where It Stands
CVS is up 56.67% over the past year, trades at 12.9x next year's earnings (well below the 22x healthcare median), and its RSI of 61.0 signals neutral-to-elevated momentum.
Key Metrics
- RSI: 61 — Near Overbought
- Trailing P/E: 45.5x
- Forward P/E: 12.9x
- PEG Ratio: 0.18
- Earnings Growth: +2.5%
- Revenue Growth: +0.1%
- Market Cap: $131.0B
- Dividend Yield: 0.03%
- 1-Year Return: 56.67%
- 52-Week High: $106.15
- 52-Week Low: $58.50
Analyst Consensus
28 Buy · 5 Hold · 0 Sell (33 analysts)
Bull Case
With forward EPS growth expected at 252.2% and a forward P/E of just 12.9x, you're getting explosive earnings growth at a price below the sector average.
Bear Case
If the forward P/E reverts up toward the trailing 45.5x, any disappointment in earnings could trigger a sharp pullback, especially with RSI at 61.0 suggesting limited room before overbought territory.
Catalyst to Watch
Watch for quarterly earnings — any miss on the 252.2% EPS growth expectation could rapidly unwind the low forward P/E thesis.